Clinical Trial

NAC for Treatment-Resistant OCD and Other Related Disorders

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled study investigating N-acetylcysteine (NAC) as an augmentation therapy for individuals with treatment-resistant obsessive-compulsive disorder (TR-OCD), studied within a broader cohort of treatment-resistant Obsessive-Compulsive and Related Disorders (OCRDs). The study's primary aim is to investigate the neurobiological mechanism by which NAC improves inhibitory control deficits in TR-OCD. This is achieved by using Magnetic Resonance Spectroscopy (MRS) to measure changes in thalamic glutamatergic metabolism. A secondary aim is to assess the clinical efficacy of this augmentation strategy on symptom severity. The central hypothesis is that improvements in inhibitory control are mediated by NAC-induced changes in brain glutamate levels.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-25; most recent amendment 2025-09-01.
Trial Details
NCT Number NCT06956157
Lead Sponsor Guangdong Provincial People's Hospital
Conditions Obsessive Compulsive Disorder (OCD)
Enrollment 90 participants
Start Date 2022-06-22
Primary Completion 2024-11-13 (estimated)
Study Completion 2025-11-13 (estimated)
Updated on ClinicalTrials.gov 2025-09-03